{"id":19263,"date":"2026-06-01T11:49:08","date_gmt":"2026-06-01T11:49:08","guid":{"rendered":"https:\/\/www.peakpoint.pk\/en\/2026\/06\/01\/advancing-risk-based-clinical-trials-pakistan\/"},"modified":"2026-06-01T11:49:08","modified_gmt":"2026-06-01T11:49:08","slug":"advancing-risk-based-clinical-trials-pakistan","status":"publish","type":"post","link":"https:\/\/www.peakpoint.pk\/en\/2026\/06\/01\/advancing-risk-based-clinical-trials-pakistan\/","title":{"rendered":"Advancing Risk-Based Clinical Trials in Pakistan"},"content":{"rendered":"<p>The Clinical Trials Unit at Aga Khan University, in collaboration with the Drug Regulatory Authority of Pakistan (DRAP), convened a two-day symposium on 15\u201316 May 2026 to advance Risk-Based Clinical Trials across the national research landscape. The event gathered regulators, researchers and industry stakeholders to discuss practical implementation of risk-based approaches and to align priorities for safer, more efficient studies.<\/p>\n<p><strong>Dr. Obaidullah<\/strong>, CEO of DRAP, and <strong>Dr. Akhtar Abbas<\/strong> were present at the symposium. In his keynote address Dr. Obaidullah congratulated the Clinical Trials Unit on its designation as a WHO Collaborating Centre for Clinical Trials and reaffirmed DRAP\u2019s commitment to strengthening an ecosystem that supports innovation, collaboration and ethical clinical research in Pakistan.<\/p>\n<p>Sessions focused on proactive monitoring, quality-driven practices and innovative regulatory perspectives, highlighting actionable steps to embed risk-based processes into trial design, oversight and management. Speakers emphasized practical tools for prioritizing risks, improving data integrity and ensuring participant safety while enabling efficient regulatory review.<\/p>\n<p>The symposium provided a forum for knowledge exchange and reinforced a collective commitment among regulators, academia and sponsors to promote high-quality, ethical and risk-focused clinical research in Pakistan. Participants left with concrete strategies to implement risk-based methodologies and to foster continued collaboration across the clinical trial ecosystem.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Explore how the Clinical Trials Unit and DRAP advanced Risk-Based Clinical Trials at a symposium on 15\u201316 May 2026 to boost quality and ethics.<\/p>\n","protected":false},"author":7,"featured_media":19262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[94],"tags":[],"class_list":["post-19263","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pakistan"],"_links":{"self":[{"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/posts\/19263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/comments?post=19263"}],"version-history":[{"count":0,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/posts\/19263\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/media\/19262"}],"wp:attachment":[{"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/media?parent=19263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/categories?post=19263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peakpoint.pk\/en\/wp-json\/wp\/v2\/tags?post=19263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}